A new type of rapid hemostasis and tissue adhesion biomaterial
The supramolecular elastin produced by genetic engineering combines Saccharomyces cerevisiae and insect protein, which solves the problems of poor adhesion and pretreatment requirements of existing hemostatic agents, achieves rapid and press-free hemostatic effect, and has good biocompatibility and healing potential.
Patent Information
- Application Number
- CN202310062847.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-13
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-01-13
AI Technical Summary
Existing hemostatic agents cannot quickly and effectively control bleeding, especially in patients with coagulation and irregular bleeding wounds, and commercial tissue adhesives have poor adhesion and require complex chemical reagents and pretreatment.
The supramolecular elastin produced by genetically engineered bacteria is used to fuse the supramolecular self-assemble the short peptide Ure2, lactic acid bacteria immunoglobulin GB1 and insect elastin R16 of Saccharomyces cerevisiae, and bind to the cell adhesion of the short peptide RGD, and the protein formed is encountered in water or blood. It can quickly adhere and stop bleeding without pressing or pretreatment.
It achieves rapid hemostasis in a few seconds, has high biocompatibility and biodegradability, can replace stitches, maintain wound fit, promote healing, and can be used in clinical medicine and medical beauty.
Smart Images

Figure CN116271197B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to a novel rapid hemostasis and tissue adhesion biomaterial. Background Art
[0002] Due to the high time sensitivity and complexity of human organ and tissue injuries, tissue and organ-related bleeding can be life-threatening and difficult to treat. Uncontrolled bleeding is one of the important causes of death worldwide, with more than 2 million deaths each year. The main purpose of existing local hemostatics is to enhance and accelerate intrinsic coagulation to achieve hemostasis. This can be achieved by rapid absorption of blood to concentrate coagulation factors, or by local delivery of procoagulants. However, due to the inherent gradual nature of blood clot formation, hemostasis by blood coagulation cannot immediately control bleeding. In addition, the rapid or pressurized blood flow that may occur at the wound site can wash away any blood clots that form, which greatly reduces the effectiveness of coagulation-dependent hemostasis; and coagulation-dependent hemostasis mechanisms are less effective in patients with anticoagulation or coagulopathy. The use of tissue adhesives is expected to achieve rapid hemostasis, but current commercial tissue adhesives have poor adhesion on the surface of bleeding tissues. At the same time, current tissue adhesives require a complex mixture of chemical reagent components with poor biocompatibility, or require pretreatment such as ultraviolet irradiation, and require continuous pressure (for more than 3 minutes) to achieve tissue adhesion, which seriously affects the application of tissue adhesives in clinical hemostasis.
[0003] The main categories of hemostatic materials currently include gauze, sponges, hydrogels, and powders. Traditional gauze and sponges stop bleeding mainly by absorbing fluid from the blood to concentrate coagulation factors. More advanced gauze and sponges based on chitosan and cellulose can aggregate blood cells and platelets, thereby further enhancing the hemostatic effect. However, due to the lack of bioadhesion, gauze and sponges need to be pressed on the bleeding wound to achieve hemostasis. Therefore, gauze and sponges cannot be used for bleeding wounds with irregular shapes and cannot be pressed, such as internal tissues and organs. Viscous hydrogels have been widely used as hemostatic materials as a physical barrier that adheres to bleeding wounds. However, blood usually weakens the adhesion between hydrogels and tissues, resulting in impaired hemostatic effects. Hemostatic powders can be directly deposited on irregularly shaped and incompressible bleeding wounds to promote hemostasis by absorbing blood. However, traditional hemostatic powders cannot form stable scabs and may even dissolve in the blood, failing to stop arterial and venous bleeding. Summary of the invention
[0004] To solve the above problems, including: 1) Existing commercial local hemostatic agents based on coagulation mechanism cannot achieve rapid hemostasis and cannot be used in patients with coagulopathy; 2) Commercial tissue adhesives have poor adhesion on the surface of bleeding tissues; 3) Current tissue adhesives require complex mixing of chemical reagent components and have poor biocompatibility; 4) Current tissue adhesives require pretreatment such as ultraviolet irradiation and require continuous pressure (for more than 3 minutes) to achieve tissue adhesion.
[0005] To this end, the present invention discloses a novel supramolecular elastin produced by genetically engineered bacteria, which sticks to water, and only 10 mg of protein powder can adhere to a 500 g weight; it sticks to blood, and can tightly adhere to the surface of a bleeding wound (including external wounds and internal organ wounds), and it only takes a few seconds to quickly stop bleeding from the wound. At the same time, the hemostatic process of this product does not require any pressing or pretreatment, and the bleeding can be stopped by simply placing the protein on the bleeding site; in addition, this product can replace suture needles, maintain the wound in an aligned state, and achieve wound healing; and this product is a pure protein product, does not require the introduction of other chemical reagent components, has good biocompatibility and biodegradability, and does not need to remove the hemostatic material after hemostasis is completed, and can be directly absorbed by cell metabolism. It is a novel biological hemostatic material and biomedical glue, and has great application potential in clinical medicine or medical aesthetics.
[0006] A supramolecular elastin protein, wherein a supramolecular self-assembling short peptide Ure2 (1-80) derived from Saccharomyces cerevisiae is fused to the N-terminus of an artificial elastin protein, wherein the amino acid sequence of the supramolecular self-assembling short peptide Ure2 (1-80) is:
[0007] MMNNNGNQVSNLSNALRQVNIGNRNSNTTTDQSNINFEFSTGVNNN NNNNSSSNNNNVQNNNSGRNGSQNNDNENNIKNT;
[0008] Artificial elastin is composed of a fusion of three parts: the partial sequence of immunoglobulin GB1 from lactic acid bacteria and the partial sequence of insect elastin R16, which provide mechanical strength, and the human cell adhesion short peptide RGD, which provides cell adhesion sites. The final artificial elastin sequence is GB1-R16-RGD.
[0009] Furthermore, the protein sequence that provides mechanical strength in the artificial elastin may be a single repeating number (GB1-R16-RGD) or a plurality of repeating numbers, such as four repeating numbers (GB1-R16)4-RGD.
[0010] Furthermore, the amino acid sequence of GB1 in the artificial elastin is:
[0011] MDTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTY DDATKTFTVTERS;
[0012] The amino acid sequence of R16 in artificial elastin is: AQTPSSQYGAP;
[0013] The amino acid sequence of RGD in artificial elastin is: RGD;
[0014] The complete sequence of supramolecular elastin is composed of a single repeat number such as Ure2(1-80)-GB1-R16-RGD, or multiple repeat numbers such as Ure2(1-80)-(GB1-R16)4-RGD.
[0015] Furthermore, the supramolecular elastin is sticky when it comes into contact with water. Only 10 mg of supramolecular elastin can adhere to a 500g weight when it comes into contact with water. Under the same operating environment, 502 glue cannot achieve the same operation.
[0016] Furthermore, a small amount of the supramolecular elastin (<1 mg) can easily adhere to various organs of rats, including the liver, heart, lungs, etc.
[0017] Furthermore, the supramolecular elastin can adhere to moist skin tissue. Taking pig skin as an example, the adhesion between proteins and pig skin was measured by lap shear test. The pig skin tissue sample was prepared in the form of a 10mm×50mm rectangle and immersed in 1×PBS buffer before use. Appropriate deionized water was added and applied to the first pig skin tissue with an area of 10mm×10mm, and then the second tissue sample was covered on the first tissue. Then the bonding force between the pig skin tissues was measured to be 960kPa;
[0018] Furthermore, the supramolecular elastin described above has a strong adhesion strength (about 1 MPa) on various substrates including high-energy surfaces (glass and metal) or low-energy surfaces (PVC and PE);
[0019] Furthermore, the supramolecular elastin is sticky when it comes into contact with blood. Only 10 mg of supramolecular elastin can also adhere to a 500 g weight when it comes into contact with blood.
[0020] Furthermore, the supramolecular elastin can achieve rapid hemostasis of organs in vivo. Taking the hemostasis of rat (200g) liver as an example, the rat liver was punctured with a needle (diameter 1.2mm) to bleed. 10mg supramolecular protein Ure2(1-80)-(GB1-R16)4-RGD was quickly applied to the puncture site, and the commercial adhesive HistoacryL containing cyanoacrylate was used as a control. The hemostasis process was recorded with a camera, and it was found that the commercial adhesive HistoacryL could not achieve hemostasis of internal organs, while the supramolecular elastin disclosed in the present invention could stop bleeding within a dozen seconds;
[0021] Furthermore, the supramolecular elastin can replace suture needles, maintain the wound closure state, and achieve wound healing and tissue regeneration;
[0022] Furthermore, the supramolecular elastin can be used as an adhesive for human eyelids, for cosmetics and skin care, and the effect of double eyelids can be achieved by bonding single eyelids to the eyelids.
[0023] Research and development of a new type of rapid hemostatic material based on supramolecular elastin. The supramolecular elastin can be produced by genetically engineered bacteria. It will stick to blood as soon as it comes into contact with it. It can tightly adhere to the surface of bleeding wounds (including external wounds and internal organ wounds), and it only takes a few seconds to achieve rapid hemostasis of the wound.
[0024] Furthermore, the hemostasis process of this product does not require any pressing or pretreatment, and the bleeding can be stopped by simply placing the protein on the bleeding area.
[0025] Furthermore, this product can replace suture needles, maintain the wound closure state, and achieve wound healing and tissue regeneration.
[0026] Furthermore, this product is a pure protein product that does not require the introduction of other chemical reagent ingredients. It has very good biocompatibility and is completely biodegradable. After hemostasis is completed, there is no need to remove the hemostatic material and it can be directly absorbed by cell metabolism. It is a new type of biological hemostatic material and biomedical glue, and has great application potential in clinical medicine or medical aesthetics.
[0027] Beneficial effects of the present invention:
[0028] The present invention utilizes a novel supramolecular elastin produced by genetically engineered bacteria, and the protein sticks to water as soon as it comes into contact with it, and only 10 mg of protein powder can adhere to a 500 g weight; it sticks to blood as soon as it comes into contact with it, and can tightly adhere to the surface of a bleeding wound (including external wounds and internal organ wounds), and it only takes a few seconds to quickly stop bleeding from the wound. At the same time, the hemostasis process of this product does not require any pressing or pretreatment, and the bleeding can be stopped by simply placing the protein on the bleeding site; in addition, this product can replace suture needles, maintain the wound in an aligned state, and achieve wound healing; and this product is a pure protein product, does not require the introduction of other chemical reagent components, has good biocompatibility and biodegradability, and does not require the removal of the hemostatic material after hemostasis is completed, and can be directly absorbed by cell metabolism. It is a novel biological hemostatic material and biomedical glue, and has great application potential in clinical medicine or medical aesthetics. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The result is that supramolecular elastin sticks to water. Only 10 mg of supramolecular elastin can adhere to a 500g weight after adding 2 microliters of water. Under the same operating environment, the same mass of 502 glue cannot achieve the same operation.
[0030] Figure 2 Supramolecular elastomeric proteins have strong adhesion strength (about 1 MPa) on high-energy surfaces (glass and metal) or low-energy surfaces (PVC and PE);
[0031] Figure 3 A small amount of supramolecular elastin (<1mg) can easily adhere to various wet organs of rats, including liver, heart, lungs, etc.
[0032] Figure 4 To show that supramolecular elastin can adhere to moist skin tissue, pig skin was used as an example to measure the adhesion between supramolecular elastin and pig skin by lap shear test. The pig skin tissue sample was prepared in the form of a 10 mm × 50 mm rectangle and immersed in 1 × PBS buffer before use. Appropriate deionized water was added and applied to the first pig skin tissue with an area of 10 mm × 10 mm. Then the second tissue sample was covered on the first tissue. Then the bonding force between the pig skin tissues was measured to be 960 kPa;
[0033] Figure 5 Supramolecular elastin sticks to blood. Only 10 mg of supramolecular elastin can stick to a 500g weight after it comes into contact with blood.
[0034] Figure 6In order to demonstrate that supramolecular elastin can achieve rapid hemostasis of organs in vivo, a rat (200 g) liver hemostasis was taken as an example, and the rat liver was punctured with a needle (1.2 mm in diameter) to bleed. 10 mg of supramolecular protein Ure2(1-80)-(GB1-R16)4-RGD was quickly applied to the puncture site, and a commercial adhesive HistoacryL containing cyanoacrylate was used as a control. The hemostasis process was recorded with a camera, and it was found that the commercial adhesive HistoacryL could not achieve internal organ hemostasis, while the supramolecular elastin disclosed in the present invention could stop bleeding within a dozen seconds;
[0035] Figure 7 Supramolecular elastin can replace suture needles, maintain the closure of wounds, and achieve wound healing;
[0036] Figure 8 H&E staining was performed on the different repaired wounds to study tissue regeneration;
[0037] Fig. 9 Masson trichrome staining was performed to show the collagen recovery in the wound area between different groups;
[0038] Fig.10 Quantitative analysis of collagen index between different groups; Each repair method was tested 6 times, and the data provided are the mean ± SD of N = 6 independent measurements, statistical analysis: one-way ANOVA and Duncan's multiple comparison test, *** refers to p < 0.001;
[0039] Fig.11 Supramolecular elastin can be used as an adhesive for human eyelids, used in cosmetics and skin care, and can achieve the effect of double eyelids by gluing single eyelids together. DETAILED DESCRIPTION
[0040] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0041] The scheme involved in the present invention is as follows:
[0042] The first object of the present invention is to provide a novel rapid hemostasis and tissue adhesion biomaterial, wherein the novel rapid hemostasis and tissue adhesion biomaterial comprises supramolecular elastin; the supramolecular elastin is formed by fusing one or more repeating units consisting of GB1 protein and R16 protein, a cell adhesion short peptide RGD and a self-assembly short peptide Ure2, wherein:
[0043] The amino acid sequence of GB1 protein is MDTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDA TKTFTVTERS, the amino acid sequence of R16 protein is AQTPSSQYGAP, the amino acid sequence of cell adhesion peptide RGD is RGD, and the amino acid sequence of self-assembly peptide Ure2 is MMNNNGNQVSNLSNALRQVNIGNRNSNTTTDQSNINFEFSTGVNNNNNN NSSSNNNNVQNNNSGRNGSQNNDNENNIKNT.
[0044] Furthermore, in the supramolecular elastin, the number of repeating units composed of GB1 protein and R16 protein is one or more.
[0045] Furthermore, the number of the repeating units composed of GB1 protein and R16 protein is 1-4.
[0046] Furthermore, the supramolecular elastic protein is obtained by directly fusing repeating units composed of GB1 protein and R16 protein, and a cell adhesion short peptide RGD and a self-assembly short peptide Ure2, without a connecting part.
[0047] Furthermore, the supramolecular elastic protein comprises, from the 5' end to the 3' end, a self-assembling short peptide Ure2, a repeating unit composed of GB1 protein and R16 protein, and a cell adhesion short peptide RGD.
[0048] Furthermore, the novel rapid hemostasis and tissue adhesion biomaterial also includes liquid substances, such as water.
[0049] Furthermore, when used, the supramolecular elastin is mixed with a liquid to obtain a novel rapid hemostatic and tissue adhesion biomaterial.
[0050] Furthermore, when applied, the supramolecular elastin is directly placed on the wound site. The supramolecular elastin can be produced by genetically engineered bacteria, and can adhere to the bleeding surface of the wound (including external wounds and internal organ wounds) tightly, and the wound can be quickly hemostatic in just a few seconds. The hemostatic process of this product does not require any pressing or pretreatment, and the specific amount of supramolecular elastin used depends on the actual situation.
[0051] Furthermore, the hemostatic material is an in vivo hemostatic agent (such as used for hemostasis of in vivo organs) or an in vitro hemostatic agent.
[0052] The second object of the present invention is to provide the use of the novel rapid hemostasis and tissue adhesion biomaterial in the preparation of medical glue (such as wound adhesive) or daily chemical products (such as substrate surface adhesive, cosmetics, skin care products, etc.).
[0053] The primers involved in the following examples are listed as follows:
[0054]
[0055] Example 1 Obtaining the amyloid fibril short peptide Ure2 (1-80)
[0056] Ure2(1-80) can be obtained from the genomic clone of Saccharomyces cerevisiae or directly obtained by gene synthesis. In this case, the gene synthesis method was used, and the amino acid sequence of the short peptide is: MMNNNGNQVSNLSNALRQVNIGNRNSNTTTDQSNINFEFSTGVNNNNNN NSSSNNNNVQNNNSGRNGSQNNDNENNIKNT.
[0057] The corresponding gene sequence can be of many kinds due to codon preference, but as long as the amino acid sequence encoded in the end is as shown above, it is the target sequence in the present invention.
[0058] Example 2 Obtaining artificial elastin
[0059] Artificial elastin is composed of three parts: the partial sequence of immunoglobulin GB1 from lactic acid bacteria and the partial sequence of insect elastin R16 provide mechanical strength, and the human cell adhesion short peptide RGD provides cell adhesion sites. The final artificial elastin sequence is GB1-R16-RGD.
[0060] The amino acid sequence of GB1 in artificial elastin is:
[0061] MDTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTY DDATKTFTVTERS;
[0062] The amino acid sequence of R16 in artificial elastin is: AQTPSSQYGAP;
[0063] The amino acid sequence of RGD in artificial elastin is: RGD;
[0064] The above protein sequences were all obtained by gene synthesis.
[0065] The protein sequence that provides mechanical strength in artificial elastin can be a single repeat number (GB1-R16-RGD) or multiple repeat numbers, such as four repeats (GB1-R16)4-RGD;
[0066] The artificial elastin sequence is obtained by gene synthesis.
[0067] Example 3 Obtaining supramolecular elastin
[0068] The amyloid fiber short peptide Ure2(1-80) was fused to the N-terminus of artificial elastin to obtain the single-repeat supramolecular elastin Ure2(1-80)-GB1-R16-RGD and the multi-repeat supramolecular elastin Ure2(1-80)-(GB1-R16)4-RGD.
[0069] Using primers Pf_Ure2(1-80)(N) / Pr_Ure2(1-80)(N), Pf_Ure2(1-80)-GB1-R16-RGD(N) / Pr_Ure2(1-80)-GB1-R16-RGD(N) and Gibson assembly kit (New England Biolabs), the amyloid fibril peptide Ure2(1-80) was fused to the N-terminus of a single-repeat artificial elastin (GB1-R16-RGD) and inserted into the NdeI / XhoI of the expression plasmid pET-28a(+), thus constructing the expression plasmid pET28a-Ure2(1-80)-GB1-R16-RGD. The amino acid sequence of Ure2(1-80)-GB1-R16-RGD is, MMNNNGNQVSSNLSNALRQVNIGNRNSNTTTDQSNINFEFSTGVNNNNNNSSSNNNNVQNNNSGRNGSQNNDNENNIKNTMDTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTERSAQTPSSQY GAPRGD.
[0070] Using primers Pf_Ure2(1-80)(N) / Pr_Ure2(1-80)(N), Pf_Ure2(1-80)-(GB1-R16)4-RGD(N) / Pr_Ure2(1-80)-(GB1-R16)4-RGD(N) and the Gibson assembly kit (New England Biolabs), the amyloid fibril peptide Ure2(1-80) was fused to the N-terminus of a single-repeat artificial elastin ((GB1-R16)4-RGD) and inserted into the NdeI / XhoI of the expression plasmid pET-28a(+), thus constructing the expression plasmid pET28a-Ure2(1-80)-(GB1-R16)4-RGD.
[0071] Example 4 Expression and purification of target protein
[0072] Preparation of culture medium: LB (Luria broth) liquid culture medium: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L NaCl, pH 7.0; sterilize with high pressure steam at 121°C for 20 min.
[0073] LB solid medium: add 2% agar powder to LB (Luria broth) liquid medium; sterilize with high pressure steam at 121°C for 20 min.
[0074] Preparation of competent E. coli:
[0075] The expression strain selected in this embodiment is Escherichia coli BL21 (DE3). Pick a single colony in 5mL LB medium and shake culture (37°C, 200rmp) overnight (about 12 hours). Take 500μL of overnight culture and transfer it to 50mL fresh LB medium, shake culture (37°C, 200rmp) until the absorbance reaches 0.35-0.6 at 600nm. Precool 0.1mol / L CaCl2 solution on ice. Pipette 25mL bacterial solution into 50mL EP tube and cool on ice for 10min. Centrifuge (3000g, 5min, 4°C), discard supernatant, add 1.666mL precooled 0.1mol / L CaCl2 solution, gently aspirate up and down with a pipette to mix well, resuspend the cells, and place on ice for 20min. Centrifuge (3000g, 5min, 4℃), discard the supernatant, add 1mL of pre-cooled mixed solution (0.1mol / LCaCl2 mixed with 10% glycerol), pipette and mix to resuspend the cells. Dispense 100μL of cell suspension into 1.5mL EP tubes in each tube and store at -70℃ for future use.
[0076] Transformation of plasmid into Escherichia coli BL21:
[0077] After the competent cells melt, transfer 1ul of plasmid into 100μL competent cells and flick gently to mix. Place on ice for 30min, heat shock in a 42℃ water bath for 90s, and place on ice for 10min. Add 1mL of fresh LB medium to the competent cell EP tube and culture in a shaker (37℃, 200rpm, 1H). Add all E. coli to the kanamycin resistance plate and spread it evenly. Place the transformation plate in a 37℃ incubator and culture it upside down for 12-24H.
[0078] Strain fermentation:
[0079] Prepare the strain activation medium (LB liquid medium), add the engineered bacteria at a ratio of 1% to the strain activation LB medium, and culture on a shaker (37°C, 200 rpm) for 10-12 hours. 600 The initial inoculum size of 0.1 was inoculated into 200 mL of fermentation medium (LB liquid medium), and cultured on a shaker (37°C, 200 rpm) until the absorbance at 600 nm reached 0.5-0.6, then 10 mM IPTG was added, and the fermentation was induced on a shaker (30°C, 200 rpm) for 10-12 hours, and the absorbance at 600 nm was measured to be 2.0-2.5.
[0080] Collecting bacteria:
[0081] After removing the supernatant by high-speed refrigerated centrifuge at 6000 rpm, 10 min, and 4°C, 200 mL of fermentation broth was transferred to 50 mL EP tubes in batches, and the obtained bacteria were placed on a vortex instrument to resuspend the bacteria evenly and then ultrasonically disrupted in an ice bath.
[0082] The ultrasonic instrument parameters were set as follows: power 900 W, probe size 12 mm, amplitude 60%, ultrasonication for 2 s and stop for 2 s, total time 2 min, and ultrasonication for a total of 6 min.
[0083] Protein purification:
[0084] Transfer the cell lysate to a 50mL EP tube, centrifuge at 8000rpm, 10min, 4℃, carefully transfer the supernatant to a clean tube without touching the precipitate below, mix the supernatant with 5mL Ni-NTA agarose purification resin, and incubate on a mixer for 1h. The water and buffer used were filtered with a 0.22um or 0.45um filter membrane before use to reduce the impact of impurities on the filler.
[0085] Wash with 10 column volumes of Stripping Buffer (50mM NaH2PO4, 300mM NaCl, 100mM EDTA, pH8.0), then wash the resin with 10-20 column volumes of deionized water, then wash the resin with 5 column volumes of 100mM NiSO4 (dissolved in deionized water), and finally re-balance with 10 column volumes of 1X PBS. The balanced resin can be used for purification experiments.
[0086] The incubated Ni-NTA agarose purification resin was loaded onto the column for gradient elution. Most of the impurities were eluted with 20 ml of 40 mM imidazole, and then the target protein was eluted with 150 mM imidazole. The protein concentration in the eluate was determined using the modified BCA protein concentration determination kit (C503051), and the eluted protein can be used for SDS-PAGE analysis. The column material was eluted with 5 volumes of ElutionBuffer, and then equilibrated with 5 volumes of Binding / Wash Buffer. Finally, the column material was washed with 5 volumes of ddH2O, and 20% ethanol protective solution was added. It was stored at 2-8°C and cannot be frozen. The collected protein eluate was dialyzed and freeze-dried to finally obtain the target protein, which was stored at 4°C.
[0087] Example 5 In vivo tissue hemostasis
[0088] All experiments were conducted in accordance with the rules of ethical animal treatment. Healthy rats weighing about 200 grams (three rats for one experiment) were randomly selected, and chloral hydrate (10%) was used to anesthetize the rats. When the rats were fully anesthetized after 10 minutes, 75% ethanol was used to disinfect the abdomen and chest of the rats. The chest cavity of the rats was then opened to expose the surface of the liver. Then, a needle (diameter 1.2mm) was used to puncture the rat liver for bleeding. 10mg of supramolecular elastin was quickly placed on the puncture bleeding site, and HistoacryL, a commercial adhesive containing cyanoacrylate, was used as a control. The hemostasis process was recorded with a camera. There were a blank group, a commercial adhesive group, and a supramolecular elastin group in the whole experiment, and the puncture hemostasis process was recorded by taking pictures.
[0089] Example 6 In vivo linear wound sealing and healing
[0090] To evaluate the effect of supramolecular elastin on linear wound sealing and healing, a linear wound was created using a scalpel with dimensions of 1 × h × w = 1 × 1 × 0.5 mm. 3 Healthy mice weighing about 20 g were selected and randomly divided into four groups (n=6). Chloral hydrate (10 wt.%) was used to anesthetize the mice. When the rats were fully anesthetized after 10 minutes, the backs of the mice were depilated and further disinfected by 75% ethanol. Except for the untreated control group, the wounds were treated with supramolecular protein, saline, medical adhesive, etc. treatment, and each group was housed individually. 10 mg of supramolecular elastin was treated with 3 uL of deionized water to treat the linear incision. A digital camera was used to take pictures of the wound. Then the fresh sections around the wound were collected quickly after the rats were euthanized. These sections were subsequently fixed in neutral buffered formalin (10%) and different grades of ethanol (70%, 80%, 90%, 95% and 100%) for sample dehydration. After that, paraffin was used to embed the samples, and the samples were cut into 2-4um thickness and further placed on slides. (H&E) staining and Masson's trichrome staining were performed by Servicebio Technology based on previous protocols. Microscopes were used to take pictures of the stained sections. One-way ANOVA and Duncan's multiple comparison test were used to determine significant mean differences (P<0.05) (SPSS) software version 17.0 (SPSS Inc., Chicago, IL, USA)).
[0091] Example 7 H&E staining
[0092] Dewax the paraffin sections to water: place the sections in xylene I for 20 min - xylene II for 20 min - anhydrous ethanol I for 5 min - anhydrous ethanol II for 5 min - 75% alcohol for 5 min, and wash with tap water.
[0093] Hematoxylin staining: Stain the sections with hematoxylin solution for 3-5 minutes, wash with tap water, differentiate with differentiation solution, wash with tap water, reblue with bluing solution, and rinse with running water.
[0094] Eosin staining: Dehydrate the sections in 85% and 95% graded alcohol for 5 min each, and then stain them in eosin solution for 5 min.
[0095] Dehydration and sealing: the slices were placed in anhydrous ethanol I for 5 min - anhydrous ethanol II for 5 min - anhydrous ethanol III for 5 min - xylene I for 5 min - xylene II for 5 min, and then transparent and sealed with neutral gum.
[0096] An upright fluorescence microscope was used for microscopic examination, collection and analysis.
[0097] Example 8 Masson trichrome staining
[0098] Dewax the paraffin sections to water: place the sections in xylene I for 20 min - xylene II for 20 min - anhydrous ethanol I for 5 min - anhydrous ethanol II for 5 min - 75% alcohol for 5 min, and wash with tap water.
[0099] The sections were immersed in Masson A solution overnight and washed with tap water.
[0100] The sections were immersed in a dye solution mixed with Masson B solution and Masson C solution in equal proportions for 1 min, washed with tap water, differentiated with 1% hydrochloric acid alcohol, and washed with tap water.
[0101] The sections were immersed in Masson D solution for 6 minutes and rinsed with tap water.
[0102] Immerse in Masson E solution for 1 minute.
[0103] Without washing, drain slightly and dye directly into Masson F solution for 2-30 seconds.
[0104] The sections were rinsed and differentiated with 1% glacial acetic acid and dehydrated in two cylinders of absolute ethanol.
[0105] Transparent sealing: Put the slices into the third cylinder of anhydrous ethanol for 5 minutes, xylene for 5 minutes to make them transparent, and then seal them with neutral gum.
[0106] An upright fluorescence microscope was used for microscopic examination, collection and analysis.
[0107] Example 9 Lap shear test using pig skin tissue as an example
[0108] In order to study the adhesion strength of supramolecular elastin to natural wet tissue, pig skin tissue was used as an example to measure the adhesion strength using an overlap shear force test. The tissue sample was first prepared into a 10mm×50mm rectangle, and then the substrate was washed with soapy water, rinsed with deionized water, and further dried overnight at room temperature. The supramolecular protein was then mixed with appropriate deionized water and applied to the substrate of the first pig skin, and then the second pig skin was covered on the first pig skin coated with supramolecular elastin, with an overlap area of 5mm×5mm; after the adhered pig skin was placed at room temperature to cure for 30 minutes, an overlap shear test was performed using a Shimadzu AGS-X universal tester at a fixed crosshead speed of 60mm / min. The maximum force was divided by the bonded area to determine the shear bond strength. All experiments were repeated three times independently.
[0109] Obviously, the above embodiments are merely examples for clear explanation and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived from these are still within the protection scope of the invention.
Claims
1. A novel rapid hemostasis and tissue adhesion biomaterial, characterized by: The novel rapid hemostasis and tissue adhesion biomaterial includes supramolecular elastin; the supramolecular elastin is formed by fusing 1 to 4 repeating units consisting of GB1 protein and R16 protein, a cell adhesion short peptide RGD and a self-assembly short peptide Ure2, wherein: The supramolecular elastic protein comprises, from the 5′ end to the 3′ end, a self-assembling short peptide Ure2, a repeating unit composed of GB1 protein and R16 protein, and a cell adhesion short peptide RGD; The amino acid sequence of GB1 protein is MDTYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTERS, the amino acid sequence of R16 protein is AQTPSSQYGAP, the amino acid sequence of cell adhesion peptide RGD is RGD, and the amino acid sequence of self-assembly peptide Ure2 is MMNNNGNQVSNLSNALRQVNIGNRNSNTTTDQSNINFEFSTGVNNNNNNNSSSNNNNVQNNNSGRNGSQNNDNENNIKNT.
2. The novel rapid hemostasis and tissue adhesion biomaterial according to claim 1 is characterized in that: The novel rapid hemostasis and tissue adhesion biomaterial also includes liquid substances.
3. The novel rapid hemostasis and tissue adhesion biomaterial according to claim 2 is characterized in that: To apply, mix supramolecular elastin with a liquid.
4. The novel rapid hemostasis and tissue adhesion biomaterial according to claim 1, characterized in that: When applied, supramolecular elastin is placed directly on the wound site.
5. The novel rapid hemostasis and tissue adhesion biomaterial according to claim 1 is characterized in that: The novel rapid hemostasis and tissue adhesion biomaterial is an in vivo hemostasis material or an in vitro hemostasis material.
6. The novel rapid hemostasis and tissue adhesion biomaterial according to claim 1 is characterized in that: The supramolecular elastic protein is obtained by directly fusing repeating units composed of GB1 protein and R16 protein, and a cell adhesion short peptide RGD and a self-assembly short peptide Ure2.
7. Use of the novel rapid hemostasis and tissue adhesion biomaterial according to any one of claims 1 to 6 in the preparation of daily chemical products, clinical medical materials or medical beauty materials.
